Loading stock data…
Bone Biologics Corporation (BBLG)
$1.07-0.01 (-0.93%)
Market ClosedLast close Jul 24
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bone Biologics Corporation in the Healthcare sector is trading at $1.07 with a market capitalization of $3M. Wall Street consensus targets $12.20 (1 analysts), implying a +1040.2% move over the next 12 months. The stock is currently near its 52-week low of $1.05, remaining 29.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 15 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +1040.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 15) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$805,054↓ | -$733,105↓ | -$715,274↑ | -$748,075↑ | -$1.04M |
| Net Income | -$765,988↓ | -$684,643↓ | -$666,737↑ | -$740,519↑ | -$1.02M |
Peer Comparison
JNJUNHPFE
Fundamentals
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.51M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-61.20%
Volume
Today's trading volume
11,424